Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
3.570
-0.200 (-5.31%)
At close: Apr 28, 2026, 4:00 PM EDT
3.552
-0.018 (-0.51%)
After-hours: Apr 28, 2026, 4:19 PM EDT
Artelo Biosciences Employees
Artelo Biosciences had 7 employees as of December 31, 2025. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,839,857
Market Cap
3.33M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| VivoSim Labs | 14 |
| Azitra | 13 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Galmed Pharmaceuticals | 6 |
| Alzamend Neuro | 6 |
| GRI Bio | 4 |
ARTL News
- 8 hours ago - Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development - GlobeNewsWire
- 8 days ago - Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile - GlobeNewsWire
- 21 days ago - Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Stock Soars After Withdrawing SEC Filing - Benzinga
- 4 weeks ago - Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength - GlobeNewsWire